BENEFIX® Clinical Pharmacology
(Coagulation Factor IX (Recombinant))
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
BeneFIX temporarily replaces the missing clotting factor IX that is needed for effective hemostasis.
12.2 Pharmacodynamics
The activated partial thromboplastin time (aPTT) is prolonged in people with hemophilia B. Treatment with factor IX concentrate may normalize the aPTT by temporarily replacing the factor IX. The administration of BeneFIX increases plasma levels of factor IX, and can temporarily correct the coagulation defect in these patients.
12.3 Pharmacokinetics
In a randomized, cross-over pharmacokinetic study, BeneFIX reconstituted in 0.234% sodium chloride diluent was shown to be pharmacokinetically equivalent to the previously marketed BeneFIX (reconstituted with Sterile Water for Injection) in 24 previously treated patients (≥12 years) at a dose of 75 IU/kg. In addition, pharmacokinetic parameters were followed up in 23 previously treated patients after repeated administration of BeneFIX for six months and found to be unchanged compared with those obtained at the initial evaluation. A summary of pharmacokinetic data are presented in Table 4:
| Abbreviations: AUC∞ = area under the plasma concentration-time curve from time zero to infinity; Cmax = peak concentration; t1/2 = plasma elimination half-life; CL = clearance; SD = standard deviation. | ||
Parameter | Baseline | Month 6 |
Cmax (IU/dL) | 54.5 ± 15.0 | 57.3 ± 13.2 |
AUC∞ (IU∙hr/dL) | 940 ± 237 | 923 ± 205 |
t1/2 (hr) | 22.4 ± 5.3 | 23.8 ± 6.5 |
CL (mL/hr/kg) | 8.47 ± 2.12 | 8.54 ± 2.04 |
Recovery | 0.73 ± 0.20 | 0.76 ± 0.18 |
Pediatric Patients (<12 years)
A population pharmacokinetic model was developed using data collected in patients aged 7 months to 60 years who received single doses of BeneFIX ranging from 50 to 75 IU/kg. The parameters estimated using the final 2-compartment model are shown in Table 5. Infants and children had higher clearance, larger volume of distribution, shorter half-life and lower recovery than adolescents and adults.
| Age Group | Infants (<2 years) | Children 2 to <6 yr | Children 6 to <12 yr | Adolescents and Adults (≥12 years) |
|---|---|---|---|---|
| Abbreviations: SD = standard deviation; Vss = volume of distribution at steady-state. | ||||
Number of subjects | 7 | 16 | 1 | 43 |
Clearance (mL/h/kg) | 13.1 ± 2.1 | 13.1 ± 2.8 | 15.5 | 8.4 ± 2.4 |
Vss (mL/kg) | 252 ± 35 | 257 ± 25 | 303 | 229 ± 57 |
Half-life (h) | 15.6 ± 1.2 | 16.7 ± 1.9 | 16.3 | 23.1 ± 4.4 |
Recovery (IU/dL per IU/kg) | 0.61 ± 0.10 | 0.60 ± 0.08 | 0.47 | 0.72 ± 0.19 |
Data from 57 PUP subjects who underwent repeat recovery testing for up to 60 months demonstrated that the average recovery was consistent over time, as shown in Figure 1.
Figure 1. Average Recovery over Time
Find BENEFIX® medical information:
Find BENEFIX® medical information:
BENEFIX® Quick Finder
Health Professional Information
Clinical Pharmacology
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
BeneFIX temporarily replaces the missing clotting factor IX that is needed for effective hemostasis.
12.2 Pharmacodynamics
The activated partial thromboplastin time (aPTT) is prolonged in people with hemophilia B. Treatment with factor IX concentrate may normalize the aPTT by temporarily replacing the factor IX. The administration of BeneFIX increases plasma levels of factor IX, and can temporarily correct the coagulation defect in these patients.
12.3 Pharmacokinetics
In a randomized, cross-over pharmacokinetic study, BeneFIX reconstituted in 0.234% sodium chloride diluent was shown to be pharmacokinetically equivalent to the previously marketed BeneFIX (reconstituted with Sterile Water for Injection) in 24 previously treated patients (≥12 years) at a dose of 75 IU/kg. In addition, pharmacokinetic parameters were followed up in 23 previously treated patients after repeated administration of BeneFIX for six months and found to be unchanged compared with those obtained at the initial evaluation. A summary of pharmacokinetic data are presented in Table 4:
| Abbreviations: AUC∞ = area under the plasma concentration-time curve from time zero to infinity; Cmax = peak concentration; t1/2 = plasma elimination half-life; CL = clearance; SD = standard deviation. | ||
Parameter | Baseline | Month 6 |
Cmax (IU/dL) | 54.5 ± 15.0 | 57.3 ± 13.2 |
AUC∞ (IU∙hr/dL) | 940 ± 237 | 923 ± 205 |
t1/2 (hr) | 22.4 ± 5.3 | 23.8 ± 6.5 |
CL (mL/hr/kg) | 8.47 ± 2.12 | 8.54 ± 2.04 |
Recovery | 0.73 ± 0.20 | 0.76 ± 0.18 |
Pediatric Patients (<12 years)
A population pharmacokinetic model was developed using data collected in patients aged 7 months to 60 years who received single doses of BeneFIX ranging from 50 to 75 IU/kg. The parameters estimated using the final 2-compartment model are shown in Table 5. Infants and children had higher clearance, larger volume of distribution, shorter half-life and lower recovery than adolescents and adults.
| Age Group | Infants (<2 years) | Children 2 to <6 yr | Children 6 to <12 yr | Adolescents and Adults (≥12 years) |
|---|---|---|---|---|
| Abbreviations: SD = standard deviation; Vss = volume of distribution at steady-state. | ||||
Number of subjects | 7 | 16 | 1 | 43 |
Clearance (mL/h/kg) | 13.1 ± 2.1 | 13.1 ± 2.8 | 15.5 | 8.4 ± 2.4 |
Vss (mL/kg) | 252 ± 35 | 257 ± 25 | 303 | 229 ± 57 |
Half-life (h) | 15.6 ± 1.2 | 16.7 ± 1.9 | 16.3 | 23.1 ± 4.4 |
Recovery (IU/dL per IU/kg) | 0.61 ± 0.10 | 0.60 ± 0.08 | 0.47 | 0.72 ± 0.19 |
Data from 57 PUP subjects who underwent repeat recovery testing for up to 60 months demonstrated that the average recovery was consistent over time, as shown in Figure 1.
Figure 1. Average Recovery over Time
Health Professional Information
{{section_name_patient}}
{{section_body_html_patient}}
Resources
Didn’t find what you were looking for? Contact us.
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Report Adverse Event
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.